GON Stock Overview
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Geron Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.20 |
| 52 Week High | US$3.49 |
| 52 Week Low | US$1.58 |
| Beta | 0.61 |
| 1 Month Change | 6.95% |
| 3 Month Change | 63.12% |
| 1 Year Change | 47.29% |
| 3 Year Change | 157.81% |
| 5 Year Change | 94.30% |
| Change since IPO | -63.83% |
Recent News & Updates
Recent updates
Shareholder Returns
| GON | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.1% | -0.2% | 0.5% |
| 1Y | 47.3% | -22.8% | 1.3% |
Return vs Industry: GON exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: GON exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| GON volatility | |
|---|---|
| GON Average Weekly Movement | 26.1% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: GON's share price has been volatile over the past 3 months.
Volatility Over Time: GON's weekly volatility has increased from 15% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 141 | Chip Scarlett | www.geron.com |
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Geron Corporation Fundamentals Summary
| GON fundamental statistics | |
|---|---|
| Market cap | €1.97b |
| Earnings (TTM) | -€171.64m |
| Revenue (TTM) | €220.93k |
8,846x
P/S Ratio-11.4x
P/E RatioIs GON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GON income statement (TTM) | |
|---|---|
| Revenue | US$237.00k |
| Cost of Revenue | US$123.74m |
| Gross Profit | -US$123.50m |
| Other Expenses | US$60.62m |
| Earnings | -US$184.13m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | -52,110.97% |
| Net Profit Margin | -77,690.72% |
| Debt/Equity Ratio | 33.0% |
How did GON perform over the long term?
See historical performance and comparison